Investors
News
Contact

About us
Inhalers
- Inhalers
- ICOres
- ICOcap
- ICOpre
- ICOone
- ICOone Nasal
- Patents
Development services
Partner with us
- Partner with us
- Iconovo Accelerator Program
Insights
- Replacing injections with inhalation
- Boost your business with an innovative inhaler partner
Investors
Search
Menu Menu

MARKET ANALYS OF ICONOVO BY ERIK PENSER BANK (ONLY IN SWEDISH)

August 19, 2019/in News /by Eva Norell

Positivt kliniskt resultat ger höjd riktkurs. Läs mera här

Share this entry

Share on Twitter
Share on LinkedIn
Share by Mail

https://www.iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png 0 0 Eva Norell https://www.iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png Eva Norell2019-08-19 11:01:292019-08-19 11:01:29MARKET ANALYS OF ICONOVO BY ERIK PENSER BANK (ONLY IN SWEDISH)

Possessing a unique combination

of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

ICONOVO AB

VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B

POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden

CONTACT

Phone: +46 46 275 67 77

VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se

CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se

SITEMAP

Home
Development services
Investors

Press releases

Positive results from Clinical Study with ICOres CLINICAL PROGRESS UPS THE VALUE OF ICONOVO’S FLAGSHIP PROJECT

Scroll to top